Roche, Dualitas team up to find bispecific drugs for immune diseases

Roche, Dualitas team up to find bispecific drugs for immune diseases

Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

Roche taps Dualitas in $1B bispecific deal - European Biotechnology Magazine

Roche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.

Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

Roche turns to Dualitas to find new bispecific approaches for immunology

Roche is turning up the heat on its hunt for next-generation bispecific antibodies in a deal that will involve screening 300,000 new combinations for inflammatory and immunology conditions. The Swiss pharma is delivering $36.5 million ...